Ngwa Ọgwụ Ọhụrụ Ọgwụgwọ nke Tumor siri ike dị elu

Nuvation Bio Inc. taa kwuputara na US Food and Drug Administration (FDA) ekpochapụla ngwa nyocha ọgwụ ọhụrụ (IND) iji nyochaa NUV-868, BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor, maka ọgwụgwọ nke etuto siri ike dị elu, gụnyere ọrịa kansa ovarian, kansa pancreatic, metastatic castration resistant prostate cancer (mCRPC), na ọrịa ara ara atọ na-adịghị mma (TNBC).

Print Friendly, PDF & Email

"Nwechapụ nke ngwa IND anyị maka NUV-868 bụ ihe dị mkpa dị mkpa maka Nuvation Bio ka ọ na-akara IND nke anọ n'ime ọnwa 14 gara aga n'ofe pipeline anyị nke ọgwụgwọ ọrịa cancer ọhụrụ na-elekwasị anya n'ọtụtụ ụdị ụbụrụ," ka David Hung, MD, onye nchoputa kwuru. , Onye isi ala, na onye isi nchịkwa nke Nuvation Bio. "A na-agba anyị ume site na nhọpụta na enwere ike imeziwanye nnabata nke NUV-868 gosipụtara na ọmụmụ ihe ọmụmụ, anyị na-atụkwa anya ịkwalite mmemme ahụ n'ime mmepe nke oge 1 n'etiti 2022."

NUV-868 na-egbochi BRD4, nke bụ isi otu n'ime ezinụlọ BET nke na-achịkwa protein nke na-achịkwa uto tumor na ọdịiche dị iche iche. Emebere NUV-868 ka ọ bụrụ nhọrọ maka BD2 karịa BD1 n'ime mbọ iji zere ọgwụ mgbochi mmachi nke ndị na-egbochi BRD4 ndị ọzọ dị ka eriri afọ (GI) na nsị ụmị ọkpụkpụ. Ọmụmụ ihe ọmụmụ egosila NUV-868 fọrọ nke nta ka ọ bụrụ ugboro 1,500 karịa nhọrọ maka BD2 karịa BD1. Ndị na-egbochi BD1/2 anaghị ahọpụta na mmepe ejikọtawo na nsogbu nnabata, nwere ike n'ihi oke mgbochi BD1.

Site na mkpochapụ nke IND a maka NUV-868 na etuto siri ike dị elu, Nuvation Bio ga-amalite usoro ọmụmụ 1/2 nke NUV-868 dị ka monotherapy yana yana olaparib ma ọ bụ enzalutamide n'ọtụtụ ụdị etuto ahụ. Usoro a (NUV-868-01) ga-amalite site na nyocha mmụba nke usoro monotherapy nke 1 na ndị ọrịa nwere etuto siri ike. A ga-amalite usoro ọmụmụ nke 1b na-enyocha NUV-868 yana olaparib na ọrịa cancer ovarian a na-agwọbu, ọrịa cancer pancreatic, mCRPC, na ndị ọrịa TNBC yana yana enzalutamide maka ndị ọrịa mCRPC na-esote usoro 2b ọmụmụ iji nwetakwuo nchekwa na ịdị irè. Ozugbo akwadoro usoro nchikota agba nke abụọ. A ga-amalitekwa ọmụmụ monotherapy nke 2 n'ime ndị ọrịa mCRPC yana nyochakwuo nchekwa na nrụpụta ọrụ.

Print Friendly, PDF & Email

Akụkọ ndi ozo

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment